EvolveImmune Therapeutics’ Post

Join us on October 19th at 8AM PT for a GEN Learning Lab, as our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what’s needed to overcome them. These challenges include the imperative for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.  https://lnkd.in/gUMCFg_7

#AACR2024 is just around the corner! We are delighted to announce that we will be presenting a poster (abstract No. 6069) featuring our oral, small molecule #BTK #degrader #UBX_303_1 for patients with relapsed/refractory B-cell malignancies. If you are attending #AACR2024, be sure to stop by and meet the #Ubix Therapeutics team. Learn more about our preclinical data and our plan for phase 1 clinical trial of #UBX_303_1. ㆍAbstract Number: 6069 ㆍDate & Time: Tuesday Apr 9, 2024, 1:30 PM - 5:00 PM ㆍLocation: Poster Section 30, Poster Board Number 28 ㆍTitle: Discovery and preclinical development of orally bioavailable potent BTK degrader, and its early clinical development for the treatment of relapsed and refractory B-cell malignancies

Join us on October 19th at 8AM PT for a GEN Learning Lab, as our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what’s needed to overcome them. These challenges include the imperative for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.  https://lnkd.in/gUMCFg_7

A beacon of precision in the dynamic world of biologics, STAT3 Monoclonal Antibody has been placed. Our STAT3 Monoclonal Antibody stands as a testament to innovation, designed to revolutionize therapeutic approaches by precisely targeting key signaling pathways. Elevate your research and therapeutic strategies with the unparalleled specificity and efficacy of our major discovery antibody. Excited to backpack on the transformative journey with GeNext Genomics, where breakthroughs become a reality. Explore the limitless potential of the STAT3 Monoclonal Antibody and witness the future of precision medicine unfold. . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #STAT3Antibody #PrecisionMedicine 

Join us on October 19th at 8AM PT for a GEN Learning Lab, as our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what's needed to overcome them. These challenges include the imperative for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.

🌟 Live from the 19th BioPharma Drug Discovery Nexus Conference! Join Lars Nieba CEO at Engimmune Therapeutics, as he unveils groundbreaking insights on coupling protein engineering with AI to develop multi-specific, soluble TCR-based cell engagers for oncology and auto-immune diseases. Don't miss this enlightening session! #BioPharma #DrugDiscovery #Innovation #NexusConference #Switzerland #Proteinengineering #AI #Cell #TCR #ImmuneDiseases #ProcurementDirect #LiveUpdate #ConferenceLive #DiscoveryConference #EuropeEvent

Join us on October 19th at 8AM PT for a GEN Learning Lab, as our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what's needed to overcome them. These challenges include the imperative for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.

We are back-to-back in San Diego! Join Jennifer Crha, Kyle Annibale, and Olga K. at Antibody Engineering & Therapeutics, December 13-16! Swing by Booth 108 for a chat on all things antibody discovery and engineering, plus grab some awesome goodies! 🎉 Don't miss our poster presentation on mapping mAb epitope diversity with HDX-MS from an alpaca polyclonal mixture. Visit poster #16 for insights! See you there! 👋  #AntibodyEngineering #Therapeutics #AntibodyDiscovery #AntibodyDevelopment

The Antibody and Engineering Therapeutics Europe conference is next week! Join Stefanie Kall, Ph.D. for a talk on how to de-risk your antibody development workflows using high-resolution thermal and colloidal stability data on your antibody constructs. Stop by booth #18 to chat more about antibody stability characterization. #AntibodyEng

Despite the critical role that #mAbs play in therapeutics today, the two commonly used approaches for identifying antigen-specific mAbs have significant drawbacks that limit the efficiency of antibody discovery. What if you could identify the best clones in hours? Namocell's Single Cell Dispensers are a game-changing technology allowing quick, safe, and gentle isolation of single cells, even at very low abundance, significantly accelerating your antibody discovery workflow. Improve your antibody discovery with Namocell. Learn more today: https://lnkd.in/gqwFYPWE #Antibodydiscovery #mAbs #monoclonalantibodies #Namocell #Singlecellanalysis #singlecelldispensers